Institutions / Perceptive Advisors LLC / Activity
Activity — Perceptive Advisors LLC
18 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | New | Exagen Inc. Common stock | $344.7K | +115K | 114,893 <0.01% of portfolio | low |
| Q1 2026 as of | New | Corcept Therapeutics Inc Common stock | $2.02M | +50K | 50,000 0.04% of portfolio | low |
| Q1 2026 as of | New | Adaptive Biotechnologies Corp Common stock | $2.12M | +153K | 152,500 0.04% of portfolio | low |
| Q1 2026 as of | New | Edesa Biotech, Inc. Common stock | $2.95M | +563K | 563,239 0.06% of portfolio | low |
| Q1 2026 as of | New | Apellis Pharmaceuticals, Inc. Common stock | $3.26M | +81K | 80,956 0.06% of portfolio | low |
| Q1 2026 as of | New | Evolus, Inc. Common stock | $5.29M | +1.3M | 1,286,862 0.10% of portfolio | medium |
| Q1 2026 as of | New | AgomAb Therapeutics NV Common stock | $6.29M | +600K | 600,000 0.12% of portfolio | medium |
| Q1 2026 as of | New | SRZN Surrozen, Inc./DE Common Stock | $6.68M | +229K | 229,393 0.13% of portfolio | medium |
| Q1 2026 as of | New | Twist Bioscience Corp Common stock | $7.13M | +150K | 150,000 0.14% of portfolio | medium |
| Q1 2026 as of | New | NMRA Neumora Therapeutics, Inc. Common Stock | $9.95M | +5.1M | 5,104,097 0.20% of portfolio | medium |
| Q1 2026 as of | New | PHAT Phathom Pharmaceuticals, Inc. Common Stock | $10.28M | +925K | 925,000 0.20% of portfolio | medium |
| Q1 2026 as of | New | EVMN Evommune, Inc. Common Stock | $10.31M | +448K | 448,350 0.20% of portfolio | medium |
| Q1 2026 as of | New | Sutro Biopharma, Inc. Common stock | $17.82M | +715K | 715,307 0.35% of portfolio | medium |
| Q1 2026 as of | New | DBVT Dbv Technologies S.A. ADR | $20.15M | +964K | 964,391 0.40% of portfolio | medium |
| Q1 2026 as of | New | Revolution Medicines, Inc. Common stock | $25.15M | +259K | 258,600 0.50% of portfolio | medium |
| Q1 2026 as of | New | 36322Q206 Common stock | $31.68M | +1.2M | 1,223,000 0.63% of portfolio | medium |
| Q1 2026 as of | New | Day One Biopharmaceuticals, Inc. Common stock | $37.64M | +1.8M | 1,755,799 0.74% of portfolio | medium |
| Q1 2026 as of | New | Ionis Pharmaceuticals Inc Common stock | $37.85M | +504K | 504,000 0.75% of portfolio | medium |